Anti-HIV drugs slash risk of virus transmission by 92 percent

May 26, 2010

People with HIV reduced the risk of handing on the AIDS virus by an astonishing 92 percent while they were taking antiretroviral drugs, according to a trial reported on Thursday.

The research provides the strongest evidence to date that drugs which treat the human immunodeficiency virus could also be incorporated into strategies for fighting HIV's spread.

In a paper published by the British journal The , doctors recruited 3,381 heterosexual couples in seven African countries.

Each couple was "serodiscordant," meaning that one of the pair was infected with while the other was uninfected.

were given to 349 individuals after their , as measured by the numbers of CD4 cells, plunged below a given threshold. The other infected individuals received a dummy pill called a .

The researchers took blood samples from the other partner every three months to see whether he or she had become infected. The trial was closely monitored by an ethics committee, and included a training course in safe sex as well as routine health checkups.

After 24 months, 103 partners who had been HIV-free at the start of the experiment had become infected with the virus by their partner.

But only one of these 103 transmissions was caused by a partner who was on antiretrovirals.

The results were confirmed by genetic fingerprinting of the virus, showing whether it had been passed on by an infected partner or by someone from outside the trial.

All in all, taking antiretroviral therapy (ART) reduced the risk of infecting someone else by 92 percent, a whopping fall that highlights the potential of these drugs as a weapon to prevent HIV, rather than just treat it, say the authors.

"Provision of ART to HIV-1 infected patients could be an effective strategy to achieve population-level reductions in HIV-1 transmission," says the paper. HIV-1 is commonest strain of the AIDS virus.

The benchmark could be when an individual has a low count of CD4 cells and high numbers of viruses in the blood, it suggests. The biggest impact could be among people whose CD4 count is lower than 200 cells per microlitre, if the research is a guide.

ART cuts down the amount of virus in blood and body fluids such as semen and vaginal mucus and so reduces exposure to a non-infected person, experts believe.

There is a caveat, though, say the authors. Even though ART may lower the risk of infecting others, the danger is not eliminated, so safe-sex counselling is essential.

The study, led by Deborah Donnell of the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle, focussed only heterosexual intercourse.

It did not look at other ways the virus can be transmitted, such as through anal intercourse, swapping drug needles or from a mother to her foetus.

ART was introduced in rich countries in the mid-1990s, but took around a decade to build up in distribution in poor nations that are bearing the brunt of the global AIDS pandemic.

For many people, the drugs have transformed the AIDS virus from a death sentence to a chronic, but manageable disease. The cocktail represses the virus, but does not eliminate it, and often has toxic side effects.

About 33.4 million people are now living with HIV, of whom more than 30 million live in low- and middle-income countries, according to the UN's World Health Organisation (WHO).

The agency's website estimates that at least 9.7 million of these are in need of ART but, as of the end of 2008, only four million people had access to the drugs.

Related Stories

Recommended for you

Researchers find latent HIV reservoirs inherently resistant to elimination by CD8+ T-cells

January 22, 2018
The latest "kick-and-kill" research to eliminate the HIV virus uncovered a potential obstacle in finding a cure. A recent study by researchers at the George Washington University (GW) found that latent HIV reservoirs show ...

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.